| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KYAT1 |
| Uniprot No | Q16773 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-372aa |
| 氨基酸序列 | MAKQLQARRLDGIDYNPWVEFVKLASEHDVVNLGQGFPDFPPPDFAVEAFQHAVSGDFMLNQYTKTFVIIIEPFFDCYEPMTMMAGGRPVFVSLKPGPIQNGELGSSSNWQLDPMELAGKFTSRTKALVLNTPNNPLGKVFSREELELVASLCQQHDVVCITDEVYQWMVYDGHQHISIASLPGMWERTLTIGSAGKTFSATGWKVGWVLGPDHIMKHLRTVHQNSVFHCPTQSQAAVAESFEREQLLFRQPSSYFVQFPQAMQRCRDHMIRSLQSVGLKPIIPQGSYFLITDISDFKRKMPDLPGAVDEPYDRRFVKWMIKNKGLVAIPVSIFYSVPHQKHFDHYIRFCFVKDEATLQAMDEKLRKWKVEL |
| 预测分子量 | 58.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KYAT1重组蛋白的模拟参考文献示例(注：部分内容为虚构，实际文献需通过学术数据库查询)：
1. **标题**：*Functional Characterization of Recombinant KYAT1 in Tryptophan Metabolism*
**作者**：Chen L, et al.
**摘要**：本研究成功表达并纯化了人源KYAT1重组蛋白，证实其在体外催化犬尿氨酸转化为犬尿酸的关键作用，并发现其活性受pH和金属离子的显著影响。
2. **标题**：*Structural Insights into KYAT1 via X-ray Crystallography*
**作者**：Wang Y, et al.
**摘要**：通过X射线晶体学解析了KYAT1重组蛋白的3D结构，揭示了其底物结合域和催化机制，为开发针对神经退行性疾病的抑制剂提供了结构基础。
3. **标题**：*KYAT1 Overexpression Alters Cellular Redox Homeostasis*
**作者**：Kim S, et al.
**摘要**：实验表明，重组KYAT1在HEK293细胞中的过表达会降低ROS水平，提示其在氧化应激调控中的潜在功能，可能与癌症和阿尔茨海默病相关。
4. **标题**：*Optimization of KYAT1 Recombinant Protein Production in E. coli*
**作者**：Zhang R, et al.
**摘要**：通过优化大肠杆菌表达系统的培养条件和诱导策略，显著提高了KYAT1重组蛋白的产量和可溶性，为大规模酶学研究奠定基础。
**建议**：实际文献请通过PubMed、Google Scholar或Web of Science搜索关键词“KYAT1 recombinant”或“KYAT1 kynurenine aminotransferase”获取。
KYAT1 (Kynurenine Aminotransferase 1), also known as CCBL1 or KAT I, is a mitochondrial enzyme encoded by the *KYAT1* gene in humans. It plays a critical role in the kynurenine pathway, a major route of tryptophan metabolism that links inflammatory signaling to neurological and immunological functions. KYAT1 catalyzes the irreversible transamination of kynurenine to produce kynurenic acid (KYNA), a bioactive metabolite with neuroactive properties. KYNA acts as an endogenous antagonist of N-methyl-D-aspartate (NMDA) receptors and α7-nicotinic acetylcholine receptors, influencing glutamatergic neurotransmission, neuroprotection, and immune regulation. Dysregulation of KYAT1 activity or KYNA levels has been implicated in neurodegenerative disorders (e.g., Alzheimer’s disease, Huntington’s disease), psychiatric conditions (e.g., schizophrenia), and inflammatory diseases.
Recombinant KYAT1 protein is engineered for research and therapeutic applications, typically produced using expression systems like *E. coli* or mammalian cell lines to ensure proper folding and post-translational modifications. Its production enables detailed biochemical studies, including enzyme kinetics, substrate specificity, and inhibitor screening. Researchers use recombinant KYAT1 to explore its role in modulating the kynurenine pathway under pathological conditions, identify potential drug targets, and develop therapies aimed at balancing neuroactive metabolites. Additionally, it serves as a tool to investigate tissue-specific expression patterns and mitochondrial dysfunction linked to metabolic diseases. As an emerging focus in precision medicine, KYAT1-related studies hold promise for addressing complex disorders at the intersection of metabolism, neurology, and immunology.
×
